Adicet Bio (ACET) Revenue & Revenue Breakdown
Adicet Bio Revenue Highlights
00
Adicet Bio Revenue by Period
Adicet Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $24.99M | 156.83% |
| 2021-12-31 | $9.73M | -45.65% |
| 2020-12-31 | $17.90M | 1699.30% |
| 2019-12-31 | $995.00K | -87.84% |
| 2018-12-31 | $8.18M | -98.54% |
| 2017-06-30 | $558.52M | 2.12% |
| 2016-06-30 | $546.95M | 7.21% |
| 2015-06-30 | $510.18M | 2.10% |
| 2014-06-30 | $499.69M | - |
| 2013-06-30 | $499.69M | 12.44% |
| 2012-06-30 | $444.39M | 7.75% |
| 2011-06-30 | $412.43M | 18.98% |
| 2010-06-30 | $346.63M | 7.43% |
| 2009-06-30 | $322.65M | -10.27% |
| 2008-06-30 | $359.59M | - |
Adicet Bio generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Adicet Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $12.89M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $-24.99M | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $24.99M | 357.02% |
| 2021-12-31 | $5.47M | 59.46% |
| 2021-09-30 | $3.43M | -28.77% |
| 2021-06-30 | $4.81M | -220.92% |
| 2021-03-31 | $-3.98M | -173.59% |
| 2020-12-31 | $5.41M | 78.67% |
| 2020-09-30 | $3.03M | -59.44% |
| 2020-06-30 | $7.46M | 273.25% |
| 2020-03-31 | $2.00M | 1.57% |
| 2019-12-31 | $1.97M | -127.94% |
| 2019-09-30 | $-7.05M | -313.29% |
| 2019-06-30 | $3.30M | 19.32% |
| 2019-03-31 | $2.77M | -100.64% |
| 2018-12-31 | $-430.51M | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $-430.51M | -474.92% |
| 2017-06-30 | $114.83M | -39.61% |
| 2017-03-31 | $190.13M | 51.43% |
| 2016-12-31 | $125.55M | -1.93% |
| 2016-09-30 | $128.02M | 3.36% |
| 2016-06-30 | $123.85M | -21.58% |
| 2016-03-31 | $157.93M | 19.94% |
| 2015-12-31 | $131.67M | -1.37% |
| 2015-09-30 | $133.50M | 21.57% |
| 2015-06-30 | $109.81M | -24.68% |
| 2015-03-31 | $145.80M | 17.80% |
| 2014-12-31 | $123.77M | -5.38% |
| 2014-09-30 | $130.80M | 1.33% |
| 2014-06-30 | $129.09M | 3.41% |
| 2014-03-31 | $124.83M | 7.14% |
| 2013-12-31 | $116.51M | -9.87% |
| 2013-09-30 | $129.26M | 4.99% |
| 2013-06-30 | $123.11M | -18.40% |
| 2013-03-31 | $150.87M | 32.39% |
| 2012-12-31 | $113.96M | 1.98% |
| 2012-09-30 | $111.75M | 0.72% |
| 2012-06-30 | $110.95M | -8.62% |
| 2012-03-31 | $121.42M | 9.67% |
| 2011-12-31 | $110.71M | 9.27% |
| 2011-09-30 | $101.32M | -16.41% |
| 2011-06-30 | $121.20M | 2.82% |
| 2011-03-31 | $117.88M | 37.58% |
| 2010-12-31 | $85.68M | -2.26% |
| 2010-09-30 | $87.66M | -17.12% |
| 2010-06-30 | $105.77M | 6.46% |
| 2010-03-31 | $99.35M | 40.10% |
| 2009-12-31 | $70.91M | 0.43% |
| 2009-09-30 | $70.61M | -5.59% |
| 2009-06-30 | $74.79M | -6.28% |
| 2009-03-31 | $79.80M | 7.53% |
| 2008-12-31 | $74.22M | -20.91% |
| 2008-09-30 | $93.84M | -10.38% |
| 2008-06-30 | $104.70M | 6.56% |
| 2008-03-31 | $98.25M | 27.43% |
| 2007-12-31 | $77.11M | - |
Adicet Bio generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Adicet Bio Revenue Breakdown
Adicet Bio Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|
| Human Health | $84.98M | $80.85M | $374.51M | $91.93M |
| Pharmaceutical Ingredients | $42.04M | $38.85M | $158.85M | $43.20M |
| Performance Chemicals | $36.63M | $44.71M | $177.99M | $50.87M |
Latest
Adicet Bio's latest quarterly revenue breakdown by segment (product or service), as of Dec 18: Human Health (51.93%), Pharmaceutical Ingredients (25.69%), and Performance Chemicals (22.38%).
Adicet Bio Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|
| Pharmaceutical Ingredients | $42.04M | $38.85M | $158.85M | $43.20M |
| Performance Chemicals | $36.63M | $44.71M | $177.99M | $50.87M |
| Human Health | $84.98M | $80.85M | $374.51M | $91.93M |
| NETHERLANDS | - | - | $11.98M | - |
| UNITED STATES | - | - | $535.70M | - |
| Asia Pacific | - | - | $30.33M | - |
| FRANCE | - | - | $36.64M | - |
| GERMANY | - | - | $96.71M | - |
Latest
Adicet Bio's latest quarterly revenue breakdown by geography, as of Dec 18: Human Health (51.93%), Pharmaceutical Ingredients (25.69%), and Performance Chemicals (22.38%).
Adicet Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALEC | Alector | $97.06M | $15.08M |
| BCYC | Bicycle Therapeutics | $26.98M | $2.68M |
| AGIO | Agios Pharmaceuticals | $26.82M | $8.96M |
| AADI | Aadi Bioscience | $24.35M | $7.21M |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| IGMS | IGM Biosciences | $2.13M | $516.00K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| FIXX | Q32 Bio | $1.16M | - |
| KROS | Keros Therapeutics | $151.00K | $37.00K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| CGEM | Cullinan Oncology | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| NKTX | Nkarta | - | - |
| TALS | Tourmaline Bio | - | - |
| ACET | Adicet Bio | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| VOR | Vor Biopharma | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| TNYA | Tenaya Therapeutics | - | - |